Navigation Links
Long-term Use of Herceptin Does Not Increase Heart Failure in Patients

CHICAGO, A five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago states that the risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time.

The research team developed a prediction model based on these findings. The model will help oncologists to assess the risk of heart failure in individual breast cancer patients before treatment with Herceptin and chemotherapy. These findings, to be announced at the Womens Cancers press briefing at the meeting, will be published in Abstract LBA513 in the ASCO proceedings.

The information we obtained from this study is essential to understanding womens risks for congestive heart failure associated with adding Herceptin to combination chemotherapy for breast cancer treatment, said Priya Rastogi, M.D., study presenter and assistant professor, University of Pittsburgh School of Medicine and assistant director of medical affairs, NSABP. Were encouraged that we found no increase in heart failure risks long-term and now are able to use this knowledge to individualize womens treatment based on their specific cardiac risk factors.

The study assessed cardiac side effects in 1,850 women with HER-2 positive breast cancer those who have abnormally high levels of the HER2/neu protein for five years. Study participants were initially randomized to receive four cycles of a standard combination chemotherapy regimen, doxorubicin and cyclophosphamide followed by paclitaxel, or doxorubicin and cyclophosphamide followed by paclitaxel and Herceptin.

The incidence of congestive heart failure was compared between the two groups. Initial three-year follow-up results reported that although Herceptin provides a clear and notable benefit to women with HER-2 po sitive breast cancer, it also causes an increased risk for congestive heart failure a 4.1 percent incidence of congestive health failure was reported in the Herceptin and chemotherapy group compared to a 0.8 percent increase in the control group.

The current study found that after five years follow-up, the incidence of congestive heart failure was virtually unchanged 3.8 percent of patients who received Herceptin and chemotherapy experienced congestive heart failure, compared to 0.9 percent of patients in the control group. Congestive heart failure was measured using a Multiple Gated Acquisition scan, or a MUGA scan a noninvasive tool that produces a moving image of the beating heart to determine the health of the cardiac ventricles.

The research team also identified possible risk factors for breast cancer patients more likely to develop congestive heart failure from adding Herceptin to combination chemotherapy. They developed a prediction model based on these factors, including hypertension, age and baseline cardiac function.

It is our hope that this model will help to individualize care for women in terms of choice of Herceptin-containing treatment regimens based on their personal risk and benefits, said Dr. Rastogi.


'"/>




Related medicine news :

1. Long-term use of calcium supplements to prevent colon cancer
2. Long-term Care Should Be A Planned Affair
3. Long-term Ibuprofen Therapy After Brain Injury Deteriorate Cognitive Abilities
4. Global AIDS Conference Calls for Long-term Strategies
5. Long-term Use of Stomach Drugs may Weaken Bones
6. Asthma Sufferers Favor Quick Relief Over Long-term Control
7. Long-term Marijuana Smoking Leads to Respiratory Complaints
8. Tamoxifen Yields Long-term Reduction in Breast Cancer Risk
9. Angioplasty Reduces Long-term Cardiac Risk in Heart Patients With silent Ischemia
10. Functional Foods Must Be Monitored to Assess Their Long-term Safety and Effectiveness
11. Cancer Drug Induces HDAC Inhibitor and Enhance Long-term Memory
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has recently highlighted ... has come up with a proprietary technique that he calls the AuraLyft ... dropped. For all ages, patients can expect to look refreshed, rejuvenated, and revitalized. ...
(Date:6/23/2017)... ... June 23, 2017 , ... PureLife Dental is pleased to announce that California ... members. As part of the amalgam separator endorsement, all CDA members may purchase an ... off the retail value. This partnership between PureLife and CDA is especially timely as ...
(Date:6/23/2017)... ... June 23, 2017 , ... Jusino Insurance ... to communities in the greater Chicago metropolitan area, is embarking on a charity ... youth in Chicago. , Founded in 1897, Hephzibah Children’s Association is one of ...
(Date:6/22/2017)... Rosa, CA (PRWEB) , ... June 22, 2017 , ... ... been named as a Top Doctor for 2017. Each year, research and information firm, ... country. First winning the title in 2015, this marks the 3rd time that ...
(Date:6/22/2017)... ... 2017 , ... The VA Maryland Health Care System has ... the Baltimore VA Medical Center, a division of the VA Maryland Health Care ... promote waste reduction and promote recycling. Also, Practice Greenhealth has recognized the ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... HAMPTON, Va. , June 14, 2017  ivWatch ... safety and effectiveness of intravenous (IV) therapy, is pleased ... in the category of Nonsurgical Hospital Supplies and Equipment ... premier awards program for the medtech industry. The award ... at the Jacob K. Javits Center in ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
(Date:6/8/2017)... 2017   Responding to Heath Ledger,s father,s ... of singer Chris Cornell in May, the mental ... a free online psychiatric drug side effects ... about psychotropic drug risks. The father of ... an accidental overdose, has called for tighter rules on prescription ...
Breaking Medicine Technology: